Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 3, 2014, Pages 317-324

  Moorthy, N S Hari Narayana ^a   Ramos, Maria J ^a   Fernandes, Pedro A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

HERG; Mahalanobis distances; Pharmacophore; QSAR; Vsurf

Indexed keywords

AROMATIC COMPOUND; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG BLOCKER; UNCLASSIFIED DRUG; ERG1 POTASSIUM CHANNEL;

ARTICLE; BIOLOGICAL ACTIVITY; HUMAN; MAHALANOBIS DISTANCE; MOLECULE; PHARMACOPHORE; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICS; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; STATISTICAL MODEL; VALIDATION STUDY;

COMPUTER SIMULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MODELS, STATISTICAL; POTASSIUM CHANNEL BLOCKERS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886842373     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.779264     Document Type: Article

References (39)

1. Thai KM, Ecker GF. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 2008;16: 4107-19.
2. Moorthy NSHN, Karthikeyan C, Trivedi P. Synthesis, cytotoxic evaluation and in silico pharmacokinetic prediction of some benzo[a]phenazine-5-sulfonic acid derivatives. Med Chem 2009;5: 549-57.
3. Bugrim A, Nikolskaya T, Nikolsky Y. Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today 2004;9:127-35.
4. Aronov AM. Predictive in silico modeling for hERG channel blockers. Drug Discov Today: Biosilico 2005;10:149-55.
5. Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. In silico based structural analysis of arylthiophene derivatives for FTase inhibitory activity, hERG and other toxic effects. J Biomol Screen 2011;16: 1037-46.
6. Durdagi S, Guo J, Lees-Miller JP, et al. Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-a-go-go-related gene 1 potassium channel (KCNH2) activator NS1643. J Pharmacol Exp Ther 2012;342:441-52.
7. Subbotina J, Yarov-Yarovoy V, Lees-Miller J, et al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. Proteins 2010;78:2922-34.
8. Vandenberg JI, Perry MD, Perrin MJ, et al. hERG K+ channels: structure, function, and clinical significance. Physiol Rev 2012; 92: 1393-478.
9. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-9.
10. Su BH, Shen MY, Esposito EX, et al. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage. J Chem Inf Model 2010;50:1304-18.
11. Moorthy NSHN, Ramos MJ, Fernandes PA. hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Adv 2011;1:1126-36.
12. Moorthy NSHN, Ramos MJ, Fernandes PA. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds. SAR QSAR Environ Res 2012;23:521-36.
13. Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of 2- piperidin-4-yl-actamide derivatives for hERG blocking and MCH R1 antagonistic activities. Curr Drug Discov Tech 2012;9:25-38.
14. Du L, Li M, You Q, Xia L. A novel structure-based virtual screening model for the hERG channel blockers. Biochem Biophy Res Comm 2007;355:889-94.
15. Durdagi S, Duff HJ, Noskov SJ. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 2011;51:463-74.
16. Du-Cuny L, Chen L, Zhang S. A critical assessment of combined ligand- and structure-based approaches to hERG channel blocker modeling. J Chem Inf Model 2011;51:2948-60.
17. Yoshida K, Niwa T. Quantitative structure-activity relationship studies on inhibition of hERG potassium channels. J Chem Inf Model 2006;46:1371-8.
18. Beshore DC, Liverton NJ, McIntyre CJ, et al. Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett 2010;20:2493-6.
19. Shen MY, Su BH, Esposito EX, et al. Comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Chem Res Toxicol 2011;24:934-49.
20. Lavalle SM, Finn P, Kavraki LE, Latombe JC. A randomized kinematics-based approach to pharmacophore-constrained conformational search and database screening. J Comput Chem 2000;21: 731-47.
21. Moorthy NSHN, Ramos MJ, Fernandes PA. Pharmacophore based screening and QSAR analysis of structurally diverse compounds for lead selection and optimization against multiple targets. OpenTox InterAction Meeting on Innovation in Predictive Toxicology; 2011 Aug 10-12; Munich, Germany.
22. De Maesschalck R, Jouan-Rimbaud D, Massart DL. The Mahalanobis distance. Chemom Intell Lab Sys 2000;50:1-18.
23. Moorthy NSHN, Sousa SF, Ramos MJ, Fernandes PA. Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. J Enz Inhibit Med Chem 2011;26:777-91.
24. Jamieson C, Moir EM, Rankovic Z, Wishart G. Medicinal chemistry of hERG optimizations: highlights and Hang-ups. J Med Chem 2006; 49:5029-46.
25. Lin A. QuaSAR-descriptors. Montreal, Canada: Chemical Computing Group Inc.; 2002.
26. Golbraikh A, Tropsha A. Beware of Q2. J Mol Graphs Model 2002;20: 269-76.
27. Moorthy NSHN, Ramos MJ, Fernandes PA. Analysis of a-glucosidase inhibitory activity of chromenone derivatives by its molecular features: a computational study. Med Chem 2011;7:526-33.
28. Choe H, Nah KH, Lee SN, et al. A novel hypothesis for the binding mode of hERG channel blockers. Biochem Biophy Res Comm 2004; 344:72-8.
29. Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of a-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemom Intell Lab Sys 2011; 109:101-12.
30. Guha R, Van Drie JH. Structure-activity landscape index: identifying and quantifying activity cliffs. J Chem Inf Model 2008;48:646-58.
31. Moorthy NSHN, Ramos MJ, Fernandes PA. Comparative structural analysis of a-glucosidase inhibitors against difference species: a computational study. Arch Pharm 2012;345:265-74.
32. Moorthy NSHN, Ramos MJ, Fernandes PA. Structural analysis of structurally diverse a-glucosidase inhibitors for active site feature analysis. J Enz Inhibit Med Chem 2012;27:649-57.
33. Cook RD. Influential observations in linear-regression. J Am Stat Assoc 1979;74:169-74.
34. Cruciani C, Crivori P, Carrupt PA, Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J Mol Struct (Theochem) 2000;503:17-30.
35. Myokai T, Ryu S, Shimizu H, Oiki S. Topological mapping of the asymmetric drug binding to the human ether-a-go-go-related gene product (hERG) potassium channel by use of tandem dimmers. Mol Pharmacol 2008; 73:1643-51.
36. Moorthy NSHN, Ramos MJ, Fernandes PA. Human ether-a-go-gorelated gene channel blockers and its structural analysis for drug design. Curr Drug Targets 2013;14:102-13.
37. Durdagi S, Subbotina J, Lees-Miller J, et al. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Curr Med Chem 2010;17:3514-32.
38. Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels. Mol Pharmacol 2008;74:1443-52.
39. Durdagi S, Deshpande S, Duff HJ, Noskov SY. Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding. J Chem Inf Model 2012;52: 2760-74.